In their aim to support researchers and clinicians, companies such as Thermo Fisher Scientific are also at the forefront of their own R&D. CLI caught up with Dr Edward Goucher, Senior Manager of Business Development, to discuss their new developments.
Frinculescu A, Coombes G, Shine T et al. Drug Test Anal 2022;doi:10.1002/dta.3277 Increasing popularity and known shortfalls in the regulation of electronic cigarettes (ECs) emphasizes the urgent need for closer content monitoring and for comprehensible information on their possible health effects.
by Xijun Min, Dr Yan Li, Liuyan Chen, Chengwei Yao, Dr Xi Qin As a traditional tumour marker for the diagnosis of early primary hepatic carcinoma (PHC), alpha fetoprotein (AFP) has a low positive rate. Serum glypican 3 (GPC3) is a novel biomarker, and the combined examination of GPC3 and AFP will provide a new […]
by Dr Cherie Ng and Dr Chaim Putterman Lupus nephritis is an immune-mediated glomerulonephritis that causes significant morbidity and mortality in patients with systemic lupus erythematous, a multisystem autoimmune disease. Non-invasive biomarkers are necessary to track disease and treatment response. Urinary ALCAM is a potential biomarker that samples the kidney and is relevant to the […]
Secretoneurin is a novel prognostic biomarker that may predict mortality in heart failure and the occurrence of ventricular arrhythmias. CLI caught up with Professor Torbjørn Omland (University of Oslo, Oslo, Norway) to find out more about it.
November 2023
Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.